RE:GCARJanuary 10, 2024 - Open letter from PanCAN President & CEO Julie Fleshman on the closure of Precision Promise platform and the strategic alliance with GCAR.
"After four years of operation and key learnings, we recently made the decision to re-evaluate the study to determine if there were opportunities to innovate and scale the study as well as create more operational efficiencies. As a result, PanCAN is pleased to announce today that it has formed a strategic alliance with the Global Coalition for Adaptive Research (GCAR), a non-profit organization who specializes in sponsoring innovative trials, including master protocols and adaptive platform trials."
" This new alliance will optimize capability and efficiencies so PanCAN can continue to invest in other areas of unmet need across the pancreatic cancer research field. "
" PanCAN will continue to treat and follow patients currently enrolled in Precision Promise until the study’s completion and then will close the current Precision Promise platform. "
"The new study sponsored by GCAR will build upon the valuable insights gained by PanCAN to date and enlists GCAR’s extensive experience in conducting patient-centric master protocols and adaptive platform trials. "
https://pancan.org/news/pancan-announces-a-strategic-alliance-with-gcar-for-precision-promise/